Go Pro
NASDAQ:AIFF

Firefly Neuroscience (AIFF) Stock Price, News & Analysis

Firefly Neuroscience logo
$1.12 -0.04 (-3.45%)
As of 10:15 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Firefly Neuroscience Stock (NASDAQ:AIFF)

Advanced

Key Stats

Today's Range
$1.11
$1.16
50-Day Range
$1.01
$1.61
52-Week Range
$0.62
$3.63
Volume
14,476 shs
Average Volume
4.31 million shs
Market Capitalization
$17.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function. In select studies, Firefly has incorporated lightweight sensor headbands to record electroencephalogram (EEG) signals, enhancing its ability to derive neurophysiological biomarkers. These digital measures are intended both for clinical trial sponsors evaluating investigational treatments and for healthcare providers seeking earlier intervention strategies.

Founded in 2017 and headquartered in the Greater Boston area, Firefly Neuroscience initially focused on Alzheimer’s disease and other forms of age‐related cognitive decline. The company collaborates with academic research centers, pharmaceutical partners and patient advocacy organizations to validate its tools across diverse populations. While its early clinical programs have been U.S.‐based, Firefly has signaled plans to expand its research partnerships and regulatory engagement in Europe and Asia.

Firefly Neuroscience is led by a management team with backgrounds in neuroscience, medical device development and digital health innovation. Through its integrated hardware-software approach, the company seeks to redefine how brain health is assessed, moving beyond episodic, clinic-based testing to continuous, data-driven insights that can accelerate drug development and enhance patient care.

AI Generated. May Contain Errors.

Firefly Neuroscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
9th Percentile Overall Score

AIFF MarketRank™: 

Firefly Neuroscience scored higher than 9% of companies evaluated by MarketBeat, and ranked 880th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Firefly Neuroscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Firefly Neuroscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Firefly Neuroscience's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Firefly Neuroscience is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Firefly Neuroscience is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Firefly Neuroscience has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.12% of the float of Firefly Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Firefly Neuroscience has a short interest ratio ("days to cover") of 5.62.
  • Change versus previous month

    Short interest in Firefly Neuroscience has recently decreased by 8.73%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Firefly Neuroscience does not currently pay a dividend.

  • Dividend Growth

    Firefly Neuroscience does not have a long track record of dividend growth.

  • News Sentiment

    Firefly Neuroscience has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Firefly Neuroscience this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for AIFF on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Firefly Neuroscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    6.90% of the stock of Firefly Neuroscience is held by insiders.

  • Percentage Held by Institutions

    4.96% of the stock of Firefly Neuroscience is held by institutions.

  • Read more about Firefly Neuroscience's insider trading history.
Receive AIFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Firefly Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AIFF Stock News Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More Headlines

AIFF Stock Analysis - Frequently Asked Questions

Firefly Neuroscience's stock was trading at $0.8750 at the beginning of the year. Since then, AIFF stock has increased by 32.6% and is now trading at $1.16.

Firefly Neuroscience, Inc. (NASDAQ:AIFF) issued its earnings results on Monday, August, 10th. The company reported ($0.10) EPS for the quarter. The company earned $0.51 million during the quarter. Firefly Neuroscience had a negative net margin of 506.23% and a negative trailing twelve-month return on equity of 106.16%.

Firefly Neuroscience shares reverse split before market open on Tuesday, August 13th 2024.The 1-3 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Top institutional shareholders of Firefly Neuroscience include BlackRock Inc. (1.20%). Insiders that own company stock include Windsor Private Capital Lp and Gerald James Benoit Jr.
View institutional ownership trends
.

Shares of AIFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Firefly Neuroscience investors own include Broadcom (AVGO), Paylocity (PCTY), Analog Devices (ADI), Advanced Micro Devices (AMD), ASML (ASML), Baidu (BIDU) and Bruker (BRKR).

Company Calendar

Last Earnings
8/10/2026
Today
8/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Technology
Sub-Industry
Healthcare Technology
Current Symbol
NASDAQ:AIFF
Previous Symbol
NASDAQ:AIFF
CIK
803578
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.88 million
Net Margins
-506.23%
Pretax Margin
-565.09%
Return on Equity
-106.16%
Return on Assets
-80.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.82
Quick Ratio
1.78

Sales & Book Value

Annual Sales
$1.14 million
Price / Sales
15.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.57 per share
Price / Book
2.03

Miscellaneous

Outstanding Shares
15,690,000
Free Float
14,529,000
Market Cap
$18.12 million
Optionable
N/A
Beta
0.57
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:AIFF) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners